| DNA ploidy as a predictive index of therapeutic response in lung cancer. |
|
In Seon Choi1, Shin Seok Lee1, Jae Beom Yang1, Kyung Ok Park1, Sang Woo Jung2 |
1Department of Internal Medicine, Chonnam University, Medical School, Kwangiu, Korea.
2Department of Pathology, Chonnam University, Medical School, Kwangiu, Korea. |
|
|
| Abstract |
Background
Although many authors have reported that the median survival time of surgically resected non-small cell lung cancer (NSCLC) was shorter in aneuploid than in diploid determined by flow cytometry, there are few reports about DNA ploidy using bronchial brushing material in all types of lung cancer.
Methods
The DNA ploidy test results of 109 consecutive patients with lung cancer were analyzed to find the relationship of DNA ploidy and anatomic or physiologic stage. And the differences of the response to various therapeutic modalities according to DNA ploidy were evaluated at least 8 weeks after the begining of the therapy.
Results
Numbers of patients with DNA aneuploid pattern or high proliferative activity (S + G2M> 22%) were not different among the various cell types of lung cancer. The relationship of DNA ploidy and anatomic or physiologic stage was not significant. However, NSCLC patients with high proliferative activity showed more advanced anatomic stage than those without that (p < 0.05). The shortterm response rate to therapy depended on the anatomic (p < 0 .005) or physiologic stages (p < 0.05) in patients with NSCLC, and not on DNA ploidy or proliferative activity.
Conclusion
DNA ploidy test using bronchial brushing material revealed that high proliferative activity means advanced anatomic stage, but it was not useful to predict the therapeutic response. |
| Key Words:
DNA ploidy, Proliferative activity, Therapeutic response, Lung cancer |
|
PDF Links
Full text via DOI
Download Citation
